Patricia B. Lehane

1.2k total citations
20 papers, 812 citations indexed

About

Patricia B. Lehane is a scholar working on Rheumatology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Patricia B. Lehane has authored 20 papers receiving a total of 812 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Rheumatology, 10 papers in Pathology and Forensic Medicine and 9 papers in Genetics. Recurrent topics in Patricia B. Lehane's work include Rheumatoid Arthritis Research and Therapies (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Lymphoma Diagnosis and Treatment (7 papers). Patricia B. Lehane is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Lymphoma Diagnosis and Treatment (7 papers). Patricia B. Lehane collaborates with scholars based in United Kingdom, United States and Canada. Patricia B. Lehane's co-authors include Ronald van Vollenhoven, Roy Fleischmann, Daniel E. Fürst, Stuart R. Lacey, Paul Emery, Edward Keystone, Clifton O. Bingham, Nicola Tyson, Neil Collinson and Paul Brunetta and has published in prestigious journals such as New England Journal of Medicine, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

Patricia B. Lehane

19 papers receiving 802 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patricia B. Lehane United Kingdom	9	368	298	231	219	171	20	812
Nicole F. Li United States	3	615 1.7×	187 0.6×	286 1.2×	282 1.3×	220 1.3×	3	925
Naonobu Sugiyama Japan	14	480 1.3×	133 0.4×	133 0.6×	359 1.6×	195 1.1×	34	871
Samantha Griffini Italy	14	408 1.1×	219 0.7×	308 1.3×	359 1.6×	149 0.9×	26	923
Jean Tayar United States	10	231 0.6×	137 0.5×	185 0.8×	163 0.7×	94 0.5×	30	846
Christina Dickson United States	10	701 1.9×	90 0.3×	177 0.8×	221 1.0×	276 1.6×	13	931
S. Berthier France	14	144 0.4×	256 0.9×	91 0.4×	148 0.7×	205 1.2×	35	662
M. C. Genovese United States	10	634 1.7×	62 0.2×	162 0.7×	228 1.0×	320 1.9×	38	842
A. Nzeusseu Toukap Belgium	14	549 1.5×	121 0.4×	65 0.3×	226 1.0×	144 0.8×	36	784
Theodora E. Markatseli Greece	14	366 1.0×	243 0.8×	50 0.2×	277 1.3×	108 0.6×	36	739
Natalia Soria Spain	5	474 1.3×	87 0.3×	53 0.2×	255 1.2×	74 0.4×	6	753

Countries citing papers authored by Patricia B. Lehane

Since Specialization

Citations

This map shows the geographic impact of Patricia B. Lehane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia B. Lehane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia B. Lehane more than expected).

Fields of papers citing papers by Patricia B. Lehane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia B. Lehane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia B. Lehane. The network helps show where Patricia B. Lehane may publish in the future.

Co-authorship network of co-authors of Patricia B. Lehane

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia B. Lehane. A scholar is included among the top collaborators of Patricia B. Lehane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia B. Lehane. Patricia B. Lehane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jamois, Candice, Leonid Gibiansky, Melissa Cheu, et al.. (2022). Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis. Clinical and Translational Science. 15(9). 2172–2183. 3 indexed citations

Brogan, Paul, Gavin Cleary, Aimee O. Hersh, et al.. (2022). Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis. Rheumatology and Therapy. 9(2). 721–734. 2 indexed citations

Werth, Victoria P., P. Joly, Daniel Mimouni, et al.. (2021). Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris. New England Journal of Medicine. 384(24). 2295–2305. 74 indexed citations

Brogan, Paul, Rae S. M. Yeung, Gavin Cleary, et al.. (2021). Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis. Arthritis & Rheumatology. 74(1). 124–133. 17 indexed citations

Merkel, Peter A., et al.. (2020). Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis. Arthritis Care & Research. 73(9). 1372–1378. 17 indexed citations

Niles, John L., et al.. (2019). 327. LONG-TERM SAFETY OF RITUXIMAB IN GRANULOMATOSIS WITH POLYANGIITIS OR MICROSCOPIC POLYANGIITIS: RESULTS OF THE FOUR-YEAR RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS REGISTRY. Lara D. Veeken. 58(Supplement_2). 1 indexed citations

Emery, Paul, et al.. (2019). Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data. Rheumatology and Therapy. 7(1). 121–131. 20 indexed citations

Berger, Joseph R., et al.. (2018). Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. Journal of NeuroVirology. 24(3). 323–331. 95 indexed citations

Brogan, Paul, Gavin Cleary, Özgür Kasapçopur, et al.. (2018). OP0332 Paediatric open-label clinical study of rituximab for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Annals of the Rheumatic Diseases. 77. 212–212. 2 indexed citations

10.

Vollenhoven, Ronald van, Roy Fleischmann, Daniel E. Fürst, Stuart R. Lacey, & Patricia B. Lehane. (2015). Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. The Journal of Rheumatology. 42(10). 1761–1766. 173 indexed citations

11.

Lehane, Patricia B., Stuart R. Lacey, E. Hessey, & Angelika Jahreis. (2014). Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 73(10). 1906–1908. 6 indexed citations

12.

Vollenhoven, Ronald van, Paul Emery, Clifton O. Bingham, et al.. (2014). 106. Long-Term Safety of Rituximab: Pooled Analysis of the Rheumatoid Arthritis Global Clinical Trial Programme Over 11 Years. Lara D. Veeken. 53(suppl_1). i97–i98.

13.

Vollenhoven, Ronald van, Paul Emery, Clifton O. Bingham, et al.. (2013). SAT0131 Long-Term Safety of Rituximab: Pooled Analysis of the Rheumatoid Arthritis Global Clinical Trial Programme Over 11 Years. Annals of the Rheumatic Diseases. 72. A625–A626. 2 indexed citations

14.

Keystone, Edward, et al.. (2012). Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with Rheumatoid Arthritis and an Inadequate Response to 1 or More Tumor Necrosis Factor Inhibitors: 5-Year Data from the REFLEX Study. The Journal of Rheumatology. 39(12). 2238–2246. 50 indexed citations

15.

Vollenhoven, Ronald van, Paul Emery, Clifton O. Bingham, et al.. (2012). Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Annals of the Rheumatic Diseases. 72(9). 1496–1502. 283 indexed citations

16.

Vollenhoven, Ronald van, Paul Emery, Clifton O. Bingham, et al.. (2012). THU0120 Long-term safety of rituximab: 10-year follow-up in the rheumatoid arthritis global clinical trial programme. Annals of the Rheumatic Diseases. 71. 195–195. 5 indexed citations

17.

Keystone, Edward, Stanley Cohen, Paul Emery, et al.. (2012). AB0526 Sustained efficacy responses and a consistent safety profile with rituximab repeat treatment over 5 years in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors in the reflex study. Annals of the Rheumatic Diseases. 71. 668–668. 1 indexed citations

18.

Mease, Philip J., Ronald van Vollenhoven, Patrick Durez, et al.. (2012). FRI0201 Analysis of infection risk in patients with limited return of peripheral B cells after a period of 2 years or more following any rituximab treatment course in RA clinical trials. Annals of the Rheumatic Diseases. 71. 381–381. 1 indexed citations

19.

Strand, Vibeke, Alexandra Balbir‐Gurman, Karel Pavelká, et al.. (2006). Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Lara D. Veeken. 45(12). 1505–1513. 59 indexed citations

20.

Fleischmann, Roy, Karel Pavelká, Andrew R. Baldassare, et al.. (2006). F.73. Preliminary Efficacy Results of Rituximab (RTX) Following a Repeat Treatment Course in Patients (Pts) with Active Rheumatoid Arthritis (RA). Clinical Immunology. 119. S76–S77. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact